Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma | 19 | 2022 | 53 | 2.480 |
Why?
|
| Glaucoma, Open-Angle | 9 | 2022 | 23 | 1.160 |
Why?
|
| Trabeculectomy | 8 | 2016 | 13 | 0.940 |
Why?
|
| Intraocular Pressure | 15 | 2022 | 62 | 0.900 |
Why?
|
| Antihypertensive Agents | 5 | 2016 | 56 | 0.790 |
Why?
|
| Laser Therapy | 3 | 2016 | 30 | 0.640 |
Why?
|
| Glaucoma Drainage Implants | 2 | 2014 | 10 | 0.560 |
Why?
|
| Optometrists | 1 | 2016 | 1 | 0.530 |
Why?
|
| Ophthalmologists | 1 | 2016 | 1 | 0.530 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2016 | 163 | 0.510 |
Why?
|
| Health Plan Implementation | 1 | 2016 | 9 | 0.500 |
Why?
|
| Medicare Part D | 1 | 2016 | 5 | 0.500 |
Why?
|
| Prescription Drugs | 1 | 2016 | 15 | 0.500 |
Why?
|
| Insurance Coverage | 1 | 2016 | 31 | 0.500 |
Why?
|
| Visual Acuity | 7 | 2014 | 111 | 0.480 |
Why?
|
| Ophthalmology | 3 | 2022 | 36 | 0.370 |
Why?
|
| Fluorouracil | 7 | 1995 | 58 | 0.360 |
Why?
|
| Retrospective Studies | 7 | 2022 | 2546 | 0.330 |
Why?
|
| Mitomycin | 5 | 1997 | 19 | 0.320 |
Why?
|
| Glaucoma, Angle-Closure | 5 | 2019 | 8 | 0.280 |
Why?
|
| Humans | 39 | 2022 | 28097 | 0.260 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 1013 | 0.230 |
Why?
|
| Male | 23 | 2019 | 13491 | 0.220 |
Why?
|
| Aged | 13 | 2016 | 5400 | 0.220 |
Why?
|
| Wound Healing | 4 | 2004 | 125 | 0.200 |
Why?
|
| Cataract Extraction | 3 | 1996 | 29 | 0.200 |
Why?
|
| Hyperopia | 2 | 2019 | 3 | 0.200 |
Why?
|
| Female | 21 | 2019 | 15156 | 0.200 |
Why?
|
| Gonioscopy | 1 | 2022 | 7 | 0.190 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2002 | 66 | 0.190 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 1997 | 32 | 0.190 |
Why?
|
| Surgeons | 1 | 2022 | 50 | 0.190 |
Why?
|
| Treatment Outcome | 5 | 2016 | 2379 | 0.180 |
Why?
|
| Aged, 80 and over | 8 | 2014 | 2021 | 0.170 |
Why?
|
| Registries | 1 | 2022 | 387 | 0.170 |
Why?
|
| Microphthalmos | 1 | 2019 | 5 | 0.160 |
Why?
|
| Ocular Hypertension | 3 | 2007 | 11 | 0.160 |
Why?
|
| Middle Aged | 17 | 2019 | 7138 | 0.160 |
Why?
|
| Postoperative Complications | 7 | 2014 | 611 | 0.150 |
Why?
|
| Eye Infections, Bacterial | 2 | 2001 | 125 | 0.150 |
Why?
|
| Retinal Degeneration | 1 | 2019 | 151 | 0.140 |
Why?
|
| Certification | 1 | 2016 | 15 | 0.130 |
Why?
|
| Specialty Boards | 1 | 2016 | 10 | 0.130 |
Why?
|
| Corneal Diseases | 3 | 1992 | 21 | 0.130 |
Why?
|
| Societies, Medical | 4 | 2022 | 93 | 0.120 |
Why?
|
| Educational Measurement | 1 | 2016 | 127 | 0.120 |
Why?
|
| Visual Field Tests | 3 | 1990 | 14 | 0.120 |
Why?
|
| Transcription Factors | 1 | 2019 | 520 | 0.120 |
Why?
|
| Membrane Proteins | 1 | 2019 | 484 | 0.120 |
Why?
|
| Chondroitin | 1 | 1994 | 4 | 0.120 |
Why?
|
| Conjunctiva | 5 | 2006 | 14 | 0.120 |
Why?
|
| Ciliary Body | 2 | 2012 | 7 | 0.120 |
Why?
|
| Prosthesis Implantation | 1 | 2014 | 26 | 0.120 |
Why?
|
| Time Factors | 4 | 2016 | 1592 | 0.110 |
Why?
|
| Endophthalmitis | 1 | 1996 | 121 | 0.110 |
Why?
|
| Visual Fields | 4 | 1990 | 33 | 0.110 |
Why?
|
| Hyaluronic Acid | 1 | 1994 | 95 | 0.110 |
Why?
|
| Lasers | 2 | 2022 | 67 | 0.100 |
Why?
|
| Sclerostomy | 1 | 1993 | 1 | 0.100 |
Why?
|
| Oklahoma | 1 | 2016 | 1007 | 0.100 |
Why?
|
| Mitomycins | 1 | 1992 | 2 | 0.100 |
Why?
|
| Lasers, Semiconductor | 1 | 2012 | 1 | 0.100 |
Why?
|
| Laser Coagulation | 1 | 2012 | 13 | 0.100 |
Why?
|
| Filtering Surgery | 2 | 2004 | 9 | 0.090 |
Why?
|
| Keratins | 1 | 1990 | 10 | 0.080 |
Why?
|
| Aqueous Humor | 3 | 2012 | 24 | 0.070 |
Why?
|
| Prostaglandins F, Synthetic | 1 | 2007 | 3 | 0.070 |
Why?
|
| Cloprostenol | 1 | 2007 | 3 | 0.070 |
Why?
|
| Eyelid Diseases | 1 | 2007 | 7 | 0.070 |
Why?
|
| Pigmentation Disorders | 1 | 2007 | 8 | 0.070 |
Why?
|
| Skin Pigmentation | 1 | 2007 | 10 | 0.070 |
Why?
|
| Amides | 1 | 2007 | 19 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1987 | 17 | 0.070 |
Why?
|
| Uracil Nucleotides | 1 | 1987 | 1 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 1987 | 37 | 0.070 |
Why?
|
| Lens Diseases | 1 | 1987 | 1 | 0.070 |
Why?
|
| Pupil | 5 | 1990 | 6 | 0.070 |
Why?
|
| Adult | 12 | 2019 | 7740 | 0.070 |
Why?
|
| Retinal Diseases | 1 | 1987 | 47 | 0.070 |
Why?
|
| Lipids | 1 | 2007 | 208 | 0.060 |
Why?
|
| Blister | 1 | 2006 | 1 | 0.060 |
Why?
|
| Liposomes | 1 | 1987 | 145 | 0.060 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2006 | 23 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 2 | 1986 | 149 | 0.060 |
Why?
|
| Animals | 7 | 2019 | 10423 | 0.050 |
Why?
|
| Diabetic Retinopathy | 1 | 1984 | 110 | 0.050 |
Why?
|
| United States | 3 | 2016 | 2146 | 0.050 |
Why?
|
| Cornea | 1 | 1983 | 68 | 0.050 |
Why?
|
| Pedigree | 2 | 2019 | 155 | 0.050 |
Why?
|
| Uveitis, Anterior | 1 | 2001 | 1 | 0.050 |
Why?
|
| Drug Utilization | 1 | 2001 | 28 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2002 | 271 | 0.040 |
Why?
|
| Postoperative Care | 3 | 1992 | 68 | 0.040 |
Why?
|
| Incidence | 2 | 2007 | 562 | 0.040 |
Why?
|
| Reoperation | 2 | 2012 | 145 | 0.040 |
Why?
|
| Surgical Wound Infection | 1 | 2001 | 105 | 0.040 |
Why?
|
| Tonometry, Ocular | 2 | 2012 | 9 | 0.040 |
Why?
|
| Moxisylyte | 2 | 1990 | 2 | 0.040 |
Why?
|
| Mydriatics | 2 | 1990 | 6 | 0.040 |
Why?
|
| Phenylephrine | 2 | 1990 | 13 | 0.040 |
Why?
|
| Sclera | 2 | 2012 | 11 | 0.040 |
Why?
|
| Injections | 4 | 1995 | 31 | 0.040 |
Why?
|
| RNA Splice Sites | 1 | 2019 | 6 | 0.040 |
Why?
|
| Refractive Errors | 1 | 2019 | 6 | 0.040 |
Why?
|
| Exons | 1 | 2019 | 42 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2019 | 14 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 1996 | 113 | 0.040 |
Why?
|
| Eye Abnormalities | 1 | 1998 | 11 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1998 | 34 | 0.040 |
Why?
|
| Family | 1 | 2019 | 98 | 0.040 |
Why?
|
| Child | 2 | 2019 | 2242 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2019 | 242 | 0.040 |
Why?
|
| Rabbits | 3 | 1993 | 277 | 0.040 |
Why?
|
| Pilot Projects | 4 | 1992 | 433 | 0.030 |
Why?
|
| Japan | 1 | 1996 | 23 | 0.030 |
Why?
|
| Ostomy | 1 | 1996 | 2 | 0.030 |
Why?
|
| Intraoperative Complications | 2 | 2006 | 47 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2016 | 84 | 0.030 |
Why?
|
| Vitreous Body | 1 | 1996 | 23 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 848 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2019 | 1146 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1995 | 48 | 0.030 |
Why?
|
| Prospective Studies | 3 | 1997 | 1248 | 0.030 |
Why?
|
| Anterior Eye Segment | 1 | 1994 | 4 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2016 | 229 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 1576 | 0.030 |
Why?
|
| Eye | 2 | 1991 | 36 | 0.030 |
Why?
|
| Bacteria | 1 | 1996 | 281 | 0.030 |
Why?
|
| Pilocarpine | 2 | 1991 | 8 | 0.030 |
Why?
|
| Iris | 5 | 1991 | 8 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 1992 | 22 | 0.020 |
Why?
|
| Epithelium | 1 | 1992 | 39 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 69 | 0.020 |
Why?
|
| Fascia | 1 | 1991 | 5 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1996 | 524 | 0.020 |
Why?
|
| Eye Color | 2 | 2007 | 2 | 0.020 |
Why?
|
| Endothelium, Corneal | 1 | 1991 | 8 | 0.020 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 1991 | 6 | 0.020 |
Why?
|
| Thiophenes | 1 | 1991 | 14 | 0.020 |
Why?
|
| Keratosis | 1 | 1990 | 1 | 0.020 |
Why?
|
| Melanosis | 1 | 1990 | 1 | 0.020 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1990 | 6 | 0.020 |
Why?
|
| Risk Factors | 1 | 1996 | 2081 | 0.020 |
Why?
|
| Sulfonamides | 1 | 1991 | 73 | 0.020 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 1990 | 1 | 0.020 |
Why?
|
| Ointments | 1 | 1990 | 6 | 0.020 |
Why?
|
| Tropicamide | 1 | 1990 | 1 | 0.020 |
Why?
|
| Mice | 1 | 2019 | 4654 | 0.020 |
Why?
|
| Xeroderma Pigmentosum | 1 | 1989 | 2 | 0.020 |
Why?
|
| Iris Diseases | 1 | 1989 | 2 | 0.020 |
Why?
|
| Uveal Neoplasms | 1 | 1989 | 8 | 0.020 |
Why?
|
| Pyridines | 1 | 1990 | 107 | 0.020 |
Why?
|
| Reference Values | 1 | 1989 | 199 | 0.020 |
Why?
|
| Skin Diseases | 1 | 1989 | 29 | 0.020 |
Why?
|
| Regression Analysis | 1 | 1989 | 210 | 0.020 |
Why?
|
| Anterior Chamber | 2 | 1991 | 6 | 0.020 |
Why?
|
| Retinal Vessels | 1 | 1988 | 72 | 0.020 |
Why?
|
| Bimatoprost | 1 | 2007 | 1 | 0.020 |
Why?
|
| Methods | 1 | 1987 | 27 | 0.020 |
Why?
|
| Light Coagulation | 1 | 1987 | 2 | 0.020 |
Why?
|
| Chromosome Disorders | 1 | 1987 | 5 | 0.020 |
Why?
|
| Aotus trivirgatus | 1 | 1987 | 1 | 0.020 |
Why?
|
| Melanoma | 1 | 1989 | 141 | 0.020 |
Why?
|
| Administration, Topical | 3 | 1991 | 30 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1987 | 75 | 0.020 |
Why?
|
| Corneal Ulcer | 1 | 1987 | 12 | 0.020 |
Why?
|
| Trabecular Meshwork | 1 | 1987 | 16 | 0.020 |
Why?
|
| Syndrome | 1 | 1987 | 78 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1987 | 76 | 0.020 |
Why?
|
| Prognosis | 1 | 1989 | 803 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 1991 | 1461 | 0.020 |
Why?
|
| Choroid | 1 | 1984 | 20 | 0.010 |
Why?
|
| Double-Blind Method | 2 | 1997 | 417 | 0.010 |
Why?
|
| Endothelium | 1 | 1983 | 28 | 0.010 |
Why?
|
| Data Collection | 1 | 2001 | 105 | 0.010 |
Why?
|
| Retina | 1 | 1984 | 436 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2001 | 78 | 0.010 |
Why?
|
| Lod Score | 1 | 1998 | 36 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1998 | 35 | 0.010 |
Why?
|
| Spouses | 1 | 1998 | 9 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1998 | 93 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1998 | 130 | 0.010 |
Why?
|
| Ophthalmic Solutions | 1 | 1997 | 27 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2001 | 971 | 0.010 |
Why?
|
| Genotype | 1 | 1998 | 456 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1997 | 414 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1997 | 607 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 1991 | 21 | 0.010 |
Why?
|
| Cicatrix | 1 | 1991 | 14 | 0.010 |
Why?
|
| Random Allocation | 1 | 1991 | 151 | 0.010 |
Why?
|
| Timolol | 1 | 1991 | 1 | 0.010 |
Why?
|
| Epinephrine | 1 | 1991 | 37 | 0.010 |
Why?
|
| Cell Count | 1 | 1991 | 86 | 0.010 |
Why?
|
| Pigmentation | 1 | 1990 | 6 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1991 | 300 | 0.010 |
Why?
|
| Exophthalmos | 1 | 1990 | 2 | 0.010 |
Why?
|
| Retinal Hemorrhage | 1 | 1990 | 7 | 0.010 |
Why?
|
| Fundus Oculi | 1 | 1990 | 15 | 0.010 |
Why?
|
| Retinal Detachment | 1 | 1990 | 11 | 0.010 |
Why?
|
| Fluorescein Angiography | 1 | 1990 | 16 | 0.010 |
Why?
|
| Sensory Thresholds | 1 | 1990 | 14 | 0.010 |
Why?
|
| Contrast Sensitivity | 1 | 1989 | 3 | 0.010 |
Why?
|
| Constriction | 1 | 1989 | 14 | 0.010 |
Why?
|
| Automation | 1 | 1989 | 19 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1990 | 391 | 0.000 |
Why?
|
| Optic Disk | 1 | 1988 | 10 | 0.000 |
Why?
|
| Dilatation | 1 | 1988 | 4 | 0.000 |
Why?
|
| Arteries | 1 | 1988 | 65 | 0.000 |
Why?
|
| Skin | 1 | 1989 | 149 | 0.000 |
Why?
|
| Actuarial Analysis | 1 | 1987 | 6 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1990 | 474 | 0.000 |
Why?
|
| Postoperative Period | 1 | 1987 | 67 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 1988 | 214 | 0.000 |
Why?
|
| Aphakia | 1 | 1986 | 3 | 0.000 |
Why?
|
| Adolescent | 1 | 1990 | 3122 | 0.000 |
Why?
|